STZ Induced Diabetes

EXCLI Journal 2023;22:274-294 – ISSN 1611-2156
Received: December 24, 2022, accepted: February 09, 2023, published: February 21, 2023
Review article:
STREPTOZOTOCIN AS A TOOL FOR INDUCTION OF RAT MODELS
OF DIABETES: A PRACTICAL GUIDE
Asghar Ghasemi , Sajad Jeddi*
Endocrine Physiology Research Center, Research Institute for Endocrine Sciences,

Shahid Beheshti University of Medical Sciences, Tehran, Iran
* Corresponding author: Sajad Jeddi, Ph.D., Endocrine Physiology Research Center,

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical
Sciences, No. 24, Arabi Street, Daneshjoo Blvd, Velenjak, P.O. Box: 19395-4763,
Tehran, Iran. E-mail: [email protected]
https://dx.doi.org/10.17179/excli2022-5720
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/).
ABSTRACT
Streptozotocin (STZ) is the most used diabetogenic chemical for creating rat models of type 1 and type 2 diabetes.
Despite ~60 years of using STZ in animal diabetes research, some prevailing views about STZ preparation and
use are not supported by evidence. Here, we provide practical guides for using STZ to induce diabetes in rats.
Susceptibility to the diabetogenic effect of STZ is inversely related to age, and males are more susceptible to STZ
than females. Wistar and Sprague-Dawley rats, the most commonly-used rat strains, are sensitive to STZ, but some
strains (e.g., Wistar-Kyoto rats) are less sensitive. STZ is mostly injected intravenously or intraperitoneally, but
its intravenous injection produces more stable hyperglycemia. Despite the prevailing view, no fasting is necessary
before STZ injection, and injection of its anomer-equilibrated solutions (i.e., more than 2 hours of dissolving) is
recommended. Mortality following the injection of diabetogenic doses of STZ is due to severe hypoglycemia
(during the first 24 h) or severe hyperglycemia (24 h after the injection and onwards). Some measures to prevent
hypoglycemia-related mortality in rats include providing access to food soon after the injection, administration of
glucose/sucrose solutions during the first 24-48 h after the injection, administration of STZ to fed animals, and
using anomer-equilibrated solutions of STZ. Hyperglycemia-related mortality following injection of high doses of
STZ can be overcome with insulin administration. In conclusion, STZ is a valuable chemical for inducing diabetes
in rats, but some practical guides should be considered to perform well-conducted and ethical studies.
Keywords: Animal model, rat, streptozotocin, diabetes
INTRODUCTION pathophysiology of diabetes to improve dia-

betes management. Because of human ethical
Diabetes, as the largest epidemic in hu-
considerations, animal models are extensively
man history (Zimmet, 2017), is among the top
used in diabetes research for pharmacological
10 causes of adult death (Zimmet, 2017;
testing, genetic studies, and understanding
Zheng et al., 2018), with a worldwide preva-
disease mechanisms (Srinivasan and
lence of ~10 % (IDF, 2019). In addition, com-
Ramarao, 2007; Franconi et al., 2008; King,
plications of diabetes impose much morbidity
2012). A prerequisite for using animal models
on affected individuals (Ghasemi and
of diabetes is knowledge and familiarity with
Norouzirad, 2019). Thus, it is not surprising
that a large amount of biomedical research is practical hints for creating the models.
Streptozotocin (STZ) is the most promi-
ongoing to offer a better understanding of the
nent diabetogenic chemical (Ghasemi et al.,
274
2014) that is widely used in experimental an- animals are not predictive of human response
imals for creating animal models of type 1 and and should be only used for generating hy-
type 2 diabetes (Samuel et al., 2014). Obtain- potheses to be tested in humans (Shanks et al.,
ing valid data from STZ-based animal models 2009). A high rate of new drugs that passed
of diabetes depends on the correct preparation preclinical studies (about nine out of ten
and use of STZ. Despite the long history and (Shanks et al., 2009)) fail in the clinical phase
extensive use of STZ in diabetes research, (Singh and Seed, 2021). For example, the av-
some essential points regarding STZ use (e.g., erage successful translation rate from animals
its preparation, suitable dose, and anomeric to clinical cancer trials is < 8 % (Mak et al.,
composition) are not always considered. 2014). Thus, animal models are excellent
These issues preclude appropriate compari- basic science tools but are not appropriate for
son of results obtained by different studies biomedical prediction. We can use the results
and cause a loss-in-translation of animal data of animal studies for building conceptual
to humans. Suboptimal preclinical data in an- models to generate testable hypotheses to ver-
imal models is one cause of the limited suc- ify in humans (Wall and Shani, 2008). In
cess rate of drugs during clinical investiga- other words, animal models of human dis-
tions (Singh and Seed, 2021). In this review, eases provide an understanding of the studied
we provide practical guides for using STZ in disease and are not intended to act as a direct
diabetes research that can assist researchers in one-to-one surrogate (Wall and Shani, 2008).
conducting better studies. Despite the limitations mentioned, animal
models have remained the best alternative
ANIMAL MODELS OF DIABETES way for testing hypotheses before human tri-
als (Wall and Shani, 2008) and are a core of
Models are needed when we can not put
preclinical drug development, which is a
our hands on the object of the study (Wall and
lengthy and expensive process (Singh and
Shani, 2008). An animal model is a living or-
Seed, 2021). An ideal animal model should
ganism in which a phenomenon of interest,
mimic natural disease patterns in humans as
similar in some aspects to humans, is studied
closely as possible (Islam and Loots du,
in a way that can not be studied in humans
2009); however, none of the models corre-
(Wall and Shani, 2008). Using animal models
sponds to human disease (Bell and Hye, 1983;
in biomedical research has a long history
Franconi et al., 2008), and each model pro-
(Wall and Shani, 2008; Bahadoran et al.,
vides advantages for studying some areas of
2020). An estimate in 2005 indicated that the
the disease (Islam and Wilson, 2012).
number of laboratory animals used for re-
Rats and mice are the animals of choice
search was about 115 million per year (Taylor
for diabetic studies (Islam and Loots du,
et al., 2008) and is still increasing (Goodman
2009), featured in 94 % of articles in the field
et al., 2015; Hudson-Shore, 2016). A report
of endocrinology (Beery and Zucker, 2011);
on toxicological studies indicates that the con-
this is mainly because of easy availability and
cordance between adverse findings in clinical
short generation interval (Srinivasan and
data with data produced in experimental ani-
Ramarao, 2007). The rat model of diabetes is
mals was 71 % (Olson et al., 2000). In addi-
more similar to human disease, for example,
tion, according to both the Nuremberg Code
in the ability of the agents to modify the dis-
(Shuster, 1997) and the Declaration of Hel-
ease (Iannaccone and Jacob, 2009). Rats have
sinki (Carlson et al., 2004), which are corner-
a short gestation period (21-22 days) and
stones for conducting ethical biomedical re-
reach sexual maturity at post-natal days 60-70
search (Shuster, 1997), animal studies need to
(Ghasemi et al., 2021), making them the first
be conducted before human trials.
choice of animal models in diabetes research
However, there is controversy concerning
(Islam and Choi, 2007). Moreover, the larger
the predictive power of animal models
size of rats compared to mice enables serial
(Shanks et al., 2009). Results obtained from
275
blood sampling more easily (Iannaccone and glucose >450 mg/dL (Reed et al., 2000). Sub-
Jacob, 2009). sequently, a higher percentage of total kcal
Rodent models of diabetes can be catego- from fat (58 %) combined with a lower dose
rized as genetic and experimentally induced. (35 mg/kg, IP) of STZ that was injected two
The latter has a lower cost and is simpler to weeks after HFD was used by Srinivasan et
induce and thus is widely used for research al. (2005). In subsequent studies, STZ in the
purposes (Islam and Loots du, 2009; Ghasemi range of 15-40 mg/kg as well as percent of
et al., 2014). Experimentally-induced animal calories from fat in the range of 30-67 %,
models of diabetes are produced by surgery, were used (Gheibi et al., 2017).
dietary handling, chemicals, or their combina- In the STZ-NA model, first introduced by
tion (Islam and Wilson, 2012; Ghasemi et al., Masiello et al., NA was injected 15 min be-
2014). The most common types of diabetes fore STZ injection to provide partial protec-
are type 1 and type 2 diabetes that are associ- tion in β-cells; stable hyperglycemia, reduced
ated with absolute and relative insulin defi- pancreatic insulin content by 60 %, and insu-
ciency, respectively (King, 2012). Chemicals lin responsiveness to glucose are among the
used for the induction of animal models of di- main advantages of this model; lack of insulin
abetes are STZ, alloxan, vactor, dithizone, 8- resistance is its main disadvantage (Masiello
hydroxyquinolone, and gold thioglucose et al., 1998). In subsequent studies that used
(Rees and Alcolado, 2005; Tripathi and this model, different doses of STZ (45-65
Verma, 2014). mg/kg, IV/IP) and NA (60-290 mg/kg, IP)
STZ, the most prominent diabetogenic was used 15-30 min before STZ injection
chemical (Ghasemi et al., 2014), is widely (Ghasemi et al., 2014).
used in experimental animals for creating an- In neonatal STZ rats, STZ (80-100 mg/kg
imal models of type 1 and type 2 diabetes (Srinivasan and Ramarao, 2007)) is injected
(Samuel et al., 2014) (Table 1). In chemically- on the day of birth (n0-STZ) (Portha et al.,
induced models of type 1 diabetes, both single 1974), two days after birth (Weir et al., 1981)
high dose of STZ [35-65 mg/kg intravenously (n2-STZ), or five days after birth (n5-STZ)
(IV) or intraperitoneally (IP)] (Srinivasan and (Wang et al., 1996). In neonatal STZ-treated
Ramarao, 2007)) and multiple injections of rats, initial transient hyperglycemia is fol-
sub-diabetogenic low dose of STZ (15 mg/kg lowed by normoglycemia, and non-fasting
for 5 consecutive days IV (Rossini et al., hyperglycemia is observed from 6-8 weeks of
1977a) or 20 mg/kg for 5 consecutive days IP age (Masiello, 2006). In addition, insulin se-
(Lukić et al., 1998)) are used in rats. Among cretion is insensitive to glucose, and abnor-
different models of experimentally-induced malities in the pancreas' α, β, and δ cells are
type 2 diabetes in rats (Ghasemi et al., 2014), observed (Weir et al., 1981). When STZ is in-
STZ is used in high-fat diet (HFD)/low doses jected at more time after birth, the regenerat-
of STZ (Reed et al., 2000; Srinivasan et al., ing capacity of β-cells is lower; 3 weeks after
2005), STZ-nicotinamide (NA) (Masiello et STZ treatment, the number of β-cells in the
al., 1998), and neonatal STZ (Portha et al., pancreas was 23 % and 48 % lower in n2-STZ
1974) models. and n5-STZ, compared to n0-STZ rats (Wang
In the initial study that introduced a com- et al., 1996). Interested readers are referred to
bined fat-fed diet and STZ, Reed et al. used a reviews on animal models of diabetes (Bell
moderate dose (50 mg/kg, IV) of STZ in male and Hye, 1983; Rees and Alcolado, 2005;
Sprague-Dawley rats after two weeks on HFD Masiello, 2006; Srinivasan and Ramarao, 2007;
(40 % of total kcal from fat) (Reed et al., Islam and Loots du, 2009; King, 2012; Ghasemi
2000); in this model, 23 % of diabetic rats had et al., 2014; Tripathi and Verma, 2014; Gheibi
serum glucose <250 mg/dL, 36 % had serum et al., 2017; Kleinert et al., 2018).
glucose 250-450 mg/dL, and 41 % had serum
276
Table 1: Rat models of streptozotocin (STZ) diabetes

Sex Strain Intervention Route of STZ Reference
administra-
tion
Type 1
diabetes
Single high Male Wistar STZ (50 and 60 mg/kg) IV Gajdosík et al.,
dose of STZ 1999
Male Sprague- STZ (50, 60, and 70 mg/kg) IV Ar'Rajab and
Dawley Ahrén, 1993
Male/ Wistar STZ (40 mg/kg) IP Mythili et al.,
female 2004
Multiple low- Male Sprague- STZ (15 mg/kg for 5 days) IV Rossini et al.,
dose of STZ Dawley 1977a
Type 2
diabetes
HFD/low-dose Male Sprague- STZ (50 mg/kg) after two IV Reed et al.,
of STZ Dawley weeks on HFD (40 % of to- 2000
tal kcal from fat)
Male Sprague- STZ (35 mg/kg) after two IP Srinivasan et
Dawley weeks on HFD (58 % of to- al., 2005
tal kcal from fat)
STZ-NA Male Wistar STZ (65 mg/kg) + NA (230 IV Masiello et al.,
mg/kg, IP) 15 min before 1998
STZ injection
Neonatal STZ
n0-STZ NR Sherman 100 mg/kg IV Portha et al.,
1974
n2-STZ Male Sprague- 90 mg/kg IP Weir et al., 1981
Dawley
n5-STZ Male/ Wistar 100 mg/kg IP Wang et al.,
female 1996
HFD, high-fat diet; NA, nicotinamide; IV, intravenous injection; IP, intraperitoneal injection; n0-STZ, n2-STZ,
and n5-STZ, streptozotocin-injected at the day of birth, two days after birth, and five days after birth, respec-
tively.
STREPTOZOTOCIN STZ metabolism in rats

Studies in rats (Spanheimer, 1989), mice
Streptozotocin (also called Streptozocin)
(Anderson et al., 1974), and humans (Kahn et
or 2-deoxy-2(([methyl(nitroso)amino]car-
al., 1975) indicate that maximum plasma con-
bonyl)amino)-(α and β)-D-glucopyranose
centrations of STZ are lower than predicted
(Thurston and Pysz, 2021), was discovered in
values, indicating a very rapid initial metabo-
1959 as a natural antibiotic produced by
lism of STZ in plasma. Immediately after in-
Streptomyces achromogenes; its toxicity to-
jecting STZ (300 mg/kg, IV) in Sprague Daw-
wards pancreatic β-cells (diabetogenic action)
ley rats, serum STZ concentration was around
was reported in 1963 (Capdevila et al., 2022)
4 mM (Spanheimer, 1989). The blood volume
by Rakieten (Lenzen, 2008). STZ molecule
in rats can be estimated via the Lee and
(molecular formula=C8H15N3O7, molecular
Blaufox formula
weight≈265 (Junod et al., 1967)) has two
parts: (1) glucopyranosyl group, which facili-
(Blood volume (mL)=0.06  Body weight (g)+0.77)
tates its uptake by pancreatic β-cells by glu-
cose transporter 2 (GLUT2) and (2) nitroso-
urea group, which destructs pancreatic β-cells (Lee and Blaufox, 1985); in a 250 g rat, it
(Capdevila et al., 2022). would be 15.77 mL. Since hematocrit is about
40 % in a 3-months-old rat (Jacob Filho et al.,
2018), plasma volume would be ~9.5 mL.
277
Therefore, STZ concentration in plasma after and peak urinary excretion observed at 10-20
injection of 300 mg/kg of STZ is expected to min after injection (Karunanayake et al.,
be ~30 mM, 7.5 times the measured value. In 1976). Only about 2-3 % of injected STZ ex-
male Swiss mice (body weight: 18-25 g), IP creted through bile over 6 hours (Karunana-
injection of STZ (100, 150, and 200 mg/kg, yake et al., 1976). STZ is rapidly removed by
IP) provided maximum plasma STZ concen- the kidney and sealing the hilum of one kid-
trations of 0.136, 0.161, and 0.224 mM ney in rats for 5 min, during and following
(Anderson et al., 1974). The blood volume in STZ injection (60 mg/kg, IV), prolongs its
male Swiss mice can be calculated from the plasma half-life by about 70 % (from 6.9 to
equation of Sluiter et al. 11.7 min) (Evan et al., 1984). 48 h after IV
injection of [14C]STZ (70 mg/kg) to Sprague-
(Blood volume (mL)=0.07146  Body weight (g)) Dawley rats in both sex, about 80 % of STZ
is excreted in the urine, 10 % in the feces and
(Sluiter et al., 1984); thus, there is 1.3-1.8 mL 10 % remains in the body, indicating rapid
blood in 18-25 g mice; since hematocrit is and extensive renal clearance of STZ
about 38 % in Swiss mice (Santos et al., (Karunanayake et al., 1974). In addition to
2016), plasma volume would be 0.8-1.1 mL. blood, STZ is distributed in the kidney, liver,
Thus, expected concentrations of plasma STZ and intestine (Karunanayake et al., 1974), in
would be 8.4, 12.6,, and 16.9 mM following which GLUT2 functions as major glucose
injection of 100, 150, and 200 mg/kg STZ, transporter (Schnedl et al., 1994).
values that are 62, 78, and 75 times higher
than the measured values. In a case study, STZ toxicity in pancreatic β-cells
STZ (200 mg) was administrated intrave- STZ has specific, rapid, and irreversible
nously to a woman to treat pancreatic cholera, cytotoxic actions on pancreatic β-cells (Junod
and the maximum plasma STZ concentration et al., 1967). Destructive effects of STZ on β-
was 0.08 mM (Kahn et al., 1975). Since cells start after 10 min of its IV injection; this
plasma volume is about 2.5 L in women notion is supported by experiments indicating
(Snyder et al., 1975), plasma STZ concentra- that IP injection of NA together with or 10
tion would be expected to be 0.3 mM, which min after STZ injection almost completely
is about 4 times higher than the measured protects the pancreas of male Wistar rats
value. against destructive effects of STZ
After injection (70 mg/kg, IV) in rats, the (Stauffacher et al., 1970). In addition, in an in
plasma concentration of STZ is very high dur- vitro study, it has been shown that more than
ing the first 1-3 min and declines to relatively 60 % of STZ is degraded in plasma obtained
low levels in 15 min (Karunanayake et al., from female Sprague-Dawley rats within 10
1974). Plasma half-life (time required that a min and completely degraded in 4 hours (Lee
given drug concentration decreases to one- et al., 1993).
half of its value (MacLeod et al., 1974)) of IV- In rodent β-cells, GLUT2 is the predomi-
injected STZ (60 mg/kg) is 5-6 min nant glucose transporter (Berger and
(Spanheimer, 1989) or 6.9 min (Evan et al., Zdzieblo, 2020). In support of this hypothesis
1984) in Sprague-Dawley rats. STZ is rapidly that the cytotoxic effect of STZ is associated
cleared from the kidney in its unchanged form with glucose transport capacity, RIN (rat in-
(Karunanayake et al., 1974) or degraded in rat sulinoma cell line) cells, which do not express
liver to produce excreted metabolites in the GLUT2 and express GLUT1 instead, show
urine (Karunanayake et al., 1976). Following resistance against STZ toxicity (65 % vs.
IV injection of STZ (70 mg/kg) to male Spra- 87 % and 49 % vs. 81 % cell viability in the
gue-Dawley rats, about 70 % of STZ ap- presence of 10 mM and 20 mM of STZ for
peared in the urine during 6 hours, with about GLUT2-expressing and untransfected RIN
40 % exerted in the first hour after injection cells, respectively) (Schnedl et al., 1994).
278
Overexpressing GLUT2 in RIN cells causes and is quite steep in the range of 25-55 mg/kg
STZ transportation with high affinity and, (Junod et al., 1969). Doses of 10 mg/kg
thus, β-cell toxicity (Schnedl et al., 1994; (Ganda et al., 1976), 20 mg/kg (Junod et al.,
Elsner et al., 2000). In addition, human islets, 1969; Ganda et al., 1976), and 25 mg/kg
in which GLUT3, and in particular, GLUT1, (Junod et al., 1969; Bar-On et al., 1976) of
play the major role in glucose transport, are STZ have no hyperglycemic effect in male
resistant to STZ (Berger and Zdzieblo, 2020). rats (Ganda et al., 1976). Doses of 30 mg/kg
Moreover, KATP channels deficient mice are and greater create progressive hyperglycemia,
resistant to the diabetogenic effect of STZ be- with plasma glucose levels reaching a plateau
cause of lower GLUT2 activity (Xu et al., at 60 mg/kg when measured 48 h after IV in-
2008). STZ causes pancreatic β-cell death jection (Ganda et al., 1976); there was no dif-
(apoptosis and necrosis) via different mecha- ference between fasting plasma glucose at
nisms, including DNA alkylation, depletion doses of 60, 80, and 120 mg/kg in male rats
of cellular NAD+ levels and thus energy dep- (Ganda et al., 1976). Doses of 30-40 mg/kg of
rivation, increasing oxidative stress, and in- STZ produce transient diabetes with sponta-
creasing nitric oxide production (Ghasemi et neous recovery, but doses of 50-70 mg/kg
al., 2014). produce long-lasting diabetes (Ar'Rajab and
Ahrén, 1993) associated with severe hyper-
Glycemic response to STZ glycemia and major clinical signs of diabetes
When diabetogenic doses of STZ (45-65 (Gajdosík et al., 1999). Although doses of 35-
mg/kg) is injected to male white Wistar rats, 65 mg/kg of STZ (IP or IV) are used for in-
a triphasic response is observed in blood glu- ducing type 1 diabetes in rats (Islam and
cose concentration (Junod et al., 1967, 1969; Loots du, 2009), 60 mg/kg has been suggested
Gajdosík et al., 1999): (1) early transient hy- as the commonly used diabetogenic dose of
perglycemia (2-4 h after STZ injection) prob- STZ in rodents (Samuel et al., 2014). How-
ably due to adrenaline response and sudden ever, it has been reported that a 40 mg/kg dose
breakdown of liver glycogen without a paral- of IP STZ is optimal for creating diabetes with
lel increase in serum insulin; (2) transient hy- moderate hyperglycemia in Wistar (male and
poglycemia (7-10 h after STZ injection) due female) rats (Mythili et al., 2004). Overall,
to increased serum insulin because of insulin STZ doses < 35 mg/kg, 40-55, and ≥ 60 mg/
release from necrotizing β-cells but without a kg are considered as low (sub-diabetogenic),
decrease in pancreatic insulin content; (3) sta- intermediate (Islam and Wilson, 2012), and
ble hyperglycemia (24 h after STZ injection high doses (Islam and Wilson, 2012), respec-
and onwards); in this phase, frank diabetes tively (Rodrigues et al., 1997; Islam and
characterized by fasting permanent hypergly- Wilson, 2012). LD50 of STZ in rats is about
cemia, relative hypoinsulinemia (i.e., serum 130 mg/kg (Junod et al., 1967), which is
insulin was comparable with fasted normal lower than that in mice (345 mg/kg (Levine et
animals but low related to coexisting hyper- al., 1980)). The dose of STZ should be opti-
glycemia), polyuria, glycosuria, and marked mized so that diabetes is successfully induced
(>90 %) decrease in pancreatic insulin con- and, simultaneously, significant mortality is
tent (Junod et al., 1969). avoided (Goyal et al., 2016). Factors that
should be considered when a dose of STZ is
Dose-dependent effects of STZ on used include animal age (Masiello et al.,
circulation glucose 1975, 1979), sex (Rossini et al., 1978; Tesch
There is an association between the dose and Allen, 2007; Kim et al., 2020; Saadane et
of STZ injected and the diabetic state induced al., 2020), strain (Rodrigues et al., 1997;
(Tancrède et al., 1983). As shown in Figure 1, Hayashi et al., 2006), and the route of admin-
the association between serum glucose and istration (Tesch and Allen, 2007). Therefore,
the dose of STZ in rats has a sigmoidal shape it is suggested that for producing permanent
279
stable hyperglycemia, researchers optimize (Tesch and Allen, 2007), including rats
the dose of STZ between 45-65 mg/kg, con- (Goyal et al., 2016). However, it should be de-
sidering the above-mentioned factors. cided case by case (Matsuzawa and
Sakazume, 1994) based on study objectives
(Weingand et al., 1996). Duration of fasting is
an important factor that can cause variations
in data during experimental studies (Kale et
al., 2009). A 16 h fasting duration has been
recommended for preclinical studies involv-
ing clinical pathology measurement in rats
(Kale et al., 2009).
Dose-dependent effects of STZ on

pancreatic insulin contents
It has been suggested that the best index
of the diabetogenic activity of STZ is the pan-
creatic insulin content 24 h after its IV injec-
tion (Junod et al., 1969). As shown in Figure
Figure 1: Relation between streptozotocin dose 2, pancreatic insulin content is progressively
and fasted (14-16 hours) and non-fasted circulat- decreased with increasing doses of the in-
ing glucose, recorded from 24 h to 4 months after jected STZ. STZ (20 mg/kg) did not affect
the streptozotocin injection in rats. Data were ob-
tained from (Junod et al., 1969; Babu and
pancreatic insulin content seven days after IV
Srinivasan, 1997; Rodrigues et al., 1997; Mythili injection (Junod et al., 1969). At the dose of
et al., 2004) and (Hoftiezer and Carpenter, 1973; 25 mg/kg of STZ, the only change observed
Bar-On et al., 1976; Ganda et al., 1976; Evan et was a decrease in pancreatic insulin content
al., 1984; Ar'Rajab and Ahrén, 1993; Rodrigues et by 36 % and 25 % following 24 h and 7 days
al., 1997; Masiello et al., 1998; Gajdosík et al.,
1999; Srinivasan et al., 2005; Akbarzadeh et al.,
of STZ injection (Junod et al., 1969). Pancre-
2007) for fasted and non-fasted states, respec- atic insulin contents were decreased by 84 %
tively. In the case that data was presented in a and 61 % 24 h after 65 and 55 mg/kg STZ in-
graph, values were extracted using Photoshop, as jection (Junod et al., 1969). It seems that fast-
previously reported (Gheibi et al., 2019). ing hyperglycemia becomes evident follow-
ing doses of STZ that deplete pancreatic insu-
lin content by 65-75 % (≥ 35 mg/kg) (Junod
The other point inferred from Figure 1 is et al., 1969). Humans maintain normoglyce-
that following STZ injection, circulation glu- mia until 50 % of the β-cells mass is lost
cose is different in fasted and non-fasted ani- (Meier, 2008). Decreased β-cell mass in long-
mals. The difference between fasted and non- lasting type 1 diabetes is about 98 % (Meier
fasted circulating glucose is more pronounced et al., 2005) due to immune-mediated β-cell
in intermediated doses (e.g., 55 mg/kg, IV) in destruction (Meier, 2008). Mostly due to
male Wistar rats (249±36 vs. 533±13 mg/dL, apoptosis-induced decreased number of β-
114 % difference). This difference is less in cells, β-cell mass is 63 % lower in obese hu-
control rats (122±5.4 vs. 135±1.8 mg/dL, mans with type 2 diabetes compared to obese
11 % difference) and those that received a nondiabetic subjects; this value was 41 %
high dose (75 mg/kg, IV) of STZ (485±14 vs. lower in lean subjects with type 2 diabetes
542±18 mg/dL, 12 % difference) (Rodrigues compared to lean nondiabetic subjects (Butler
et al., 1997). Fasting before the blood sam- et al., 2003).
pling in rodents is recommended to reduce the
variation in blood glucose readings associated
with feeding habits. It is recommended that
blood glucose be measured in fasted animals
280
rapid equilibrium between extracellular and

intracellular glucose (Berger and Zdzieblo,
2020). In contrast, Km of glucokinase (4-10
mM), which phosphorylates glucose inside
the β-cell is much lower than GLUT2; in fact,
glucose uptake in rat β-cells is about 66 and
88 times faster than glucose utilization by glu-
cokinase (Berger and Zdzieblo, 2020). These
data indicate that glucokinase-dependent glu-
cose phosphorylation is the rate-limiting fac-
tor for glucose utilization in β-cell rather than
GLUT2-mediated glucose uptake (Berger and
Zdzieblo, 2020). In addition, infusion of glu-
cose (13.75 mmol/kg) to male rats had no pro-
tective effect against STZ (60 mg/kg, IV), and
Figure 2: Relation between streptozotocin dose plasma glucose concentrations were compa-
and pancreatic insulin content, recorded from 24
h to 35 days after the streptozotocin injection in
rable between saline-infused and glucose-in-
rats. Data were obtained from (Junod et al., 1967, fused rats (422±7.5 vs. 408±27.9 mg/dL) 48 h
1969; Stauffacher et al., 1970; Robbins et al., later (Ganda et al., 1976). On the other hand,
1980; Rodrigues et al., 1997). In the case that 3-O-methyl glucose (6.39 mmol/kg) and 2-
data was presented in a graph, values were ex- deoxyglucose (7.5 mmol/kg), which are non-
tracted using Photoshop, as previously reported
(Gheibi et al., 2019).
metabolized analogs of glucose, provided
protection against STZ (60 mg/kg)-induced
hyperglycemia by about 70 % and 40 %, re-
IS FASTING BEFORE STZ INJECTION spectively (Ganda et al., 1976), indicating that
ADVANTAGEOUS? β-cell glucose metabolism, not GLUT2-medi-
ated uptake, is the limiting factor for STZ ef-
Before the injection of STZ in rats, differ-
ficacy (Chaudhry et al., 2013). In further sup-
ent fasting times have been used in studies,
port, following the injection of a diabetogenic
including 6 h (Cruz et al., 2021), 12 h
dose of STZ (70 mg/kg, IV) in rats, small
(Mostafavinia et al., 2016), 16 h (Junod et al.,
amounts lower than that found in the blood
1969), 20 h (Katada and Ui, 1977), 24 h
reach the pancreas (Karunanayake et al.,
(Hoftiezer and Carpenter, 1973; Ganda et al.,
1974). Plasma glucose concentrations vary
1976; Rossini et al., 1977b), and 72 h (Chi et
between a minimum of 55 mg/dL (3.1 mM)
al., 2007). Some authors also vaguely re-
during fasting to a maximum of 160 mg/dL
ported that STZ was injected after overnight
(8.9 mM) after a meal, and its daily average is
fasting (Gajdosík et al., 1999; Su et al., 2006).
about 90 mg/dL (5.0 mM) (Rizza et al., 1980;
What is the rationale behind the injection of
Gerich, 1993; Defronzo, 2009; Gerich, 2010).
STZ to fasted animals? The answer is to min-
Considering Michaelis-Menten equation
imize the competition between glucose and
Vmax
STZ for GLUT2-mediated uptake into the β- (V0 = ) , where V0 , is the initial transport
K
cell (King, 2012; Chaudhry et al., 2013). Nev- 1+ m
C
ertheless, is this answer supported by evi-
rate; Vmax , is maximum rate of transport, Km ,
dence?
Glucose uptake in rat β-cells is mainly is glucose concentration at which V0 equals to
mediated through GLUT2 (Berger and Vmax
, and C, is the extracellular glucose con-
Zdzieblo, 2020), which has a very high Vmax 2
(32 mmol/min/L islet space) and a high Km centration, rates of glucose transport by
(17 mM) for glucose (Johnson et al., 1990). GLUT2 are 15 %, 23 %, and 34 % at glucose
The high transport capacity of GLUT2 causes concentrations of 3.1, 5.0, and 8.9 mM. These
281
values indicate that even at the postprandial addition, fasting glucose was in normal range
state, GLUT2 works with about one-third of whereas non-fasting glucose was in the dia-
its capacity for transporting glucose and that betic range (Islam and Choi, 2007).
competition between STZ and glucose for up- Overall, a short answer to the question
take by β-cells has little importance. posed in the heading is that fasting before
Results of a study in male mice indicate STZ injection to induce diabetes is unneces-
that injecting multiple low doses of STZ was sary and not recommended in mice (de la
equally effective for inducing hyperglycemia, Garza-Rodea et al., 2010; Chaudhry et al.,
glucose intolerance, β-cell dysfunction, and 2013) and rats (Goyal et al., 2016).
β-cell loss in fed and fasted (6 h: 10:00-16:00)
mice and therefore recommends that fasting PREPARATION OF STZ SOLUTION
before STZ administration is not required STZ is a pale yellow, freeze-dried powder
(Chaudhry et al., 2013). Another report in (Frost et al., 2015) stored at -20 ºC (de la
male and female mice indicates that injecting Garza-Rodea et al., 2010). STZ is a hydro-
a single dose of STZ in non-fasted animals philic agent (Lenzen, 2008) and is found in
can successfully induce diabetes (de la Garza- two anomeric forms of α and β (de la Garza-
Rodea et al., 2010). There are also reports of Rodea et al., 2010). Based on the first reports
injecting STZ in non-fasting male Wistar on the diabetogenic action of STZ, STZ solu-
(Tancrède et al., 1983) and Sprague-Dawley tion is prepared and maintained in the ice-cold
(Ar'Rajab and Ahrén, 1993) rats with success- acidic (pH 4.5) citrate buffer and is used im-
ful induction of hyperglycemia. mediately after its preparation (Junod et al.,
Injection of STZ in non-fasted rats pre- 1967, 1969; Ganda et al., 1976; Mythili et al.,
vents metabolic stress and weight loss 2004; Tesch and Allen, 2007). It has been
(Chaudhry et al., 2013). Fasting decreases rat mentioned that STZ solution is stable only at
body weight by about 5 % (Matsuzawa and a pH of 4.2 to 4.5 (Mythili et al., 2004) and is
Sakazume, 1994) and 10 % (Maejima and not stable in an unbuffered aqueous solution
Nagase, 1991) following 16 h and 24 h, re- (Oles, 1978). Therefore, freshly prepared and
spectively. Fasting causes a time-dependent immediate injection of STZ for inducing dia-
decrease in body weight in both male (0.25- betes has become routine among most re-
0.48 %/h over 4-48 h) and female (0.22- searchers (de la Garza-Rodea et al., 2010;
0.50 %/h over 4-48 h) Wistar rats (Kale et al., King, 2012). Most researchers use acidic (pH
2009). Fasting also alters serum glucose in 4.0-4.7) citrate-buffered solutions to prepare
normal (Kale et al., 2009) and diabetic (Islam STZ for injection (Bar-On et al., 1976;
and Choi, 2007) rats. 16 h, 24 h, and 48 h of Karunanayake et al., 1976; Rossini et al.,
fasting caused 42.2 %, 43.7 %, and 51.1 % 1977b; Robbins et al., 1980; Tancrède et al.,
decrease in serum glucose concentrations in 1983; Ar'Rajab and Ahrén, 1993; Babu and
normal male Wistar rats and 27.6 %, 35.2 %, Srinivasan, 1997; Gajdosík et al., 1999;
and 41.4 % in normal female Wistar rats Mythili et al., 2004; L'Abbate et al., 2007;
(Kale et al., 2009). Shorter fasting periods (4 Tesch and Allen, 2007; Lebed et al., 2008;
and 8 hours) did not affect serum glucose con- Palsamy and Subramanian, 2011; Ramzy et
centrations in rats (Kale et al., 2009), which al., 2014). Others use saline (Evan et al.,
indicates their wastefulness before STZ injec- 1984), acidified (pH, 4.3-4.5) saline (Junod et
tion, unlike recommendations by some papers al., 1967, 1969; Stauffacher et al., 1970;
(Goyal et al., 2016). In male Sprague-Dawley Hoftiezer and Carpenter, 1973), and rarely
rats treated with HFD and STZ (30 mg/kg, phosphate buffer saline (pH, 7.4) (Chaudhry
IP), non-fasting blood glucose, as measured et al., 2013), or saline (pH 7.2) (Rodrigues et
one week after STZ injection, was 317 % al., 1997) to prepare STZ for injection. The
higher than fasting glucose, measured 48-72 concentration of citrate buffer, which is the
h after STZ injection (371 vs. 89 mg/dL); in
282
most used solvent, varies 10000-fold and con- study indicates that STZ solution prepared in
centrations of 0.01 mM (Ramzy et al., 2014), PBS buffer (pH 7.4) and kept at 37 ºC is al-
5 mM (Anderson et al., 1974; Portha et al., most completely degraded in 4 hours (Lee et
1974), 10 mM (Karunanayake et al., 1976; al., 1993). This data suggest that the essential
Tesch and Allen, 2007), 50 mM (Bar-On et factors for maintaining the stability of STZ
al., 1976; Schnedl et al., 1994; Kim et al., are probably acidic citrate buffer, protection
2020), and 100 mM (Ganda et al., 1976; against light, and low temperature. This sug-
Robbins et al., 1980; Ar'Rajab and Ahrén, gestion is partly in line with previous recom-
1993; Babu and Srinivasan, 1997; Gajdosík et mendations that STZ gives the most stable so-
al., 1999; Lebed et al., 2008; Palsamy and lution when dissolved in acidic (pH 4.5) cit-
Subramanian, 2011) have been used. Some rate buffer (Lenzen, 2008) and should be
researchers emphasized that they prepared the maintained in aluminum foil-wrapped tubes
solution immediately before injection (Junod because it is light-sensitive (Tesch and Allen,
et al., 1969; Karunanayake et al., 1974, 1976; 2007; Furman, 2021). However, an acidic so-
Tancrède et al., 1983; Rodrigues et al., 1997; lution can cause red blood cell hemolysis in
Gajdosík et al., 1999; L'Abbate et al., 2007), rats and provide pain and discomfort to the
and others highlighted that they prepared STZ animal (Lee et al., 1993). STZ has been used
solution within 5 min (Bar-On et al., 1976; for treating pancreatic neuroendocrine tumors
Chaudhry et al., 2013; Ramzy et al., 2014), 10 since 1982 after the approval of the FDA (US
min (Ganda et al., 1976), or even 30-45 sec Food and Drug Administration) (Capdevila et
(Rossini et al., 1977b) before the injection. al., 2022). In addition to 1 g of STZ, each vial
Based on the prevailing notion that dis- of STZ powder contains 200-220 mg citric
solved STZ is quickly degraded, there are acid (Akbarzadeh et al., 2007; El-Rashedy et
some recommendations in the literature, in- al., 2013; Frost et al., 2015), providing a pH
cluding (a) STZ is stable only at a pH of 4.2 of 3.5-4.5 after dissolving in 9.5 mL of cold
to 4.5 (Mythili et al., 2004), and to minimize 0.9 % NaCl (Akbarzadeh et al., 2007; Frost et
decomposition of the drug, it needs to be pre- al., 2015). STZ solutions are maintained at 2-
pared in ice-cold citrate buffer and maintained 8 ºC and away from light (Akbarzadeh et al.,
on ice (Mythili et al., 2004); (b) citrate buffer 2007; El-Rashedy et al., 2013; Frost et al.,
used for STZ preparation should be fresh or 2015).
frozen as aliquots at -20 ºC (Tesch and Allen, STZ is found in two anomeric forms of α
2007). Therefore STZ is usually administered and β (de la Garza-Rodea et al., 2010). The
in NaCl or citrate buffer solutions with acidic proportion of α anomer varies between differ-
pH (4.0 to 4.8) (Lee et al., 1993). Does evi- ent STZ lots (de la Garza-Rodea et al., 2010).
dence support these recommendations? For example, the α-STZ percentage in lots
It has been reported that STZ in citrate prepared by the Upjohn Company (1970 to
buffer (100 mM, pH 4) is stable for 4 h at 1975) ranged from 25 % to 90 %, which can
room temperature with about 4 % degradation act as a source of variation (Rossini et al.,
(Spanheimer, 1989). After dissolving STZ in 1977b). α-anomer is further toxic compared to
100 mM citrate buffer, pH=4.5, kept in the β-anomer against pancreatic β-cells (de la
dark at 4 ºC, its rate of degradation was 0.1 % Garza-Rodea et al., 2010). Injecting α-STZ
daily as measured for 27 months; when kept (90 % α-anomer and 10 % β-anomer) at doses
at room temperature, its rate of degradation of 30, 35, 40, and 45 mg/kg IV to fasted (24
was 1 % daily as measured over 5 days of h) male Sprague-Dawley rats caused higher
storage (de la Garza-Rodea et al., 2010). STZ blood glucose levels 48 h after the injection
degradation, prepared in citrate buffered sa- compared to injecting β-STZ (25 % α-anomer
line (pH 4.4) kept in the dark at 37 ºC, was and 75 % β-anomer) (Rossini et al., 1977b).
20 % during 14 days (about 1.4 % daily) Still, it did not occur for lower doses (10 and
(Premilovac et al., 2017). However, another 20 mg/kg) and higher doses (50, 55, and 60
283
mg/kg) (Rossini et al., 1977b). These data in- 4 ºC and injected 2-3 hours after dissolution)
dicate that α-anomer is more diabetogenic at compared to freshly-prepared (injected within
doses of 30, 35, 40, and 45 mg/kg (Rossini et 15 min after dissolution) solution (7 % vs.
al., 1977b). 36 %) (de la Garza-Rodea et al., 2010).
During the first 15 min after preparing dif- To sum up, injecting anomer-equilibrated
ferent lots of STZ (84-88 % α-anomer) solu- solutions of STZ (i.e., more than 2 hours of
tion, α-anomer is 3-20-folds higher in the so- dissolving) prepared in acidic (pH 4.5) citrate
lution than β anomer (de la Garza-Rodea et buffer solution and kept in the dark (alumi-
al., 2010). With time, α-anomer decreases and num foil-wrapped tubes) is recommended for
β-anomer increases, and equilibrium between inducing diabetes in laboratory animals.
anomers (50:50) is achieved during 60 min
(de la Garza-Rodea et al., 2010) or 60-90 min SEX DIFFERENCES IN RESPONSE
(Oles, 1978) after dissolution. After 2 h and TO STZ
onwards, a ratio of 44 % α and 56 % β is Glucose homeostasis (Mauvais-Jarvis,
found in the STZ solution (de la Garza-Rodea 2018), β-cell function (Gannon et al., 2018),
et al., 2010). The rate of attainment equilib- insulin sensitivity (Mauvais-Jarvis, 2018),
rium in the mutarotation reaction is pH-de- and type 2 diabetes (Franconi et al., 2008) are
pendent and is slightly faster in lower pH sex-dependent phenomena. Women have
(Oles, 1978). Following IP STZ injection in about 6 % more β-cells than men (Marchese
non-fasted mice, blood glucose was 20 % et al., 2015), and more severe adverse health
higher in mice that received freshly-dissolved consequences of diabetes occur in women
STZ, which mainly contains α-anomer, com- than men (Franconi et al., 2008). Impaired
pared to those that received anomer-equili- fasting glucose is more prevalent in men, and
brated solutions (de la Garza-Rodea et al., impaired glucose tolerance is more prevalent
2010). in women (Mauvais-Jarvis, 2018). However,
Despite the prevailing view that STZ a survey conducted in 2009 in the field of en-
should be injected freshly and immediately docrinology reports that about 11.2 % of ani-
after dissolution, it has been recommended mal research was done in both sexes, only
that the induction of diabetes in animals 20.7 % in females, and 66 % in males (2.1 %
should be done by anomer-equilibrated solu- unsuccessful in specifying the sex of experi-
tions (de la Garza-Rodea et al., 2010). This mental models), indicating a male bias of
practice allows more reliable comparison of 3.2:1 (Beery and Zucker, 2011). This sex bias
results from different laboratories by elimi- causes a generalization of findings in men to
nating the effect of STZ anomer (de la Garza- women without appropriate justification
Rodea et al., 2010) and can help to provide (Beery and Zucker, 2011). Surprisingly, some
more reproducible results when various lots papers suggest that researchers prefer male
of STZ are used (Rossini et al., 1977b). In ad- animals over females to diminish mortality
dition, the relative amounts of the STZ and increase the efficacy of STZ (Goyal et al.,
anomers in a given preparation must be re- 2016). This recommendation is unlike NIH
ported in studies of STZ-induced β-cell ne- policy to avoid over-reliance on male-only
crosis (Rossini et al., 1977b), an issue that is animal models and to balance both sexes in
not the case in most studies. In support of in- the preclinical studies (Clayton and Collins,
jecting anomer-equilibrated solutions of STZ 2014) that have been further discussed else-
for creating an animal model of diabetes, the where (McCullough et al., 2014). Interested
rate of reported mortality following IP STZ readers are referred to an excellent review by
injection to non-fated mice was significantly Ritz et al. for addressing sex and gender con-
lower after injection of the anomer-equili- siderations in basic biomedical research (Ritz
brated solution (stored solution of STZ in 0.1 et al., 2014).
M citrate buffer, pH=4.5, kept in the dark at
284
Different sensitivity to STZ-induced dia- Mass of β-cells is regulated by the balance in

betes has been reported in male and female β-cell growth, i.e., changes in cell size/vol-
mice. In CD-1 mice, following STZ injection ume (hypertrophy vs. hypotrophy) and β-cell
(40 mg/kg, IP) for 5 days, plasma glucose number (cell production by neogenesis and
concentrations, measured five days after the replication vs. cell loss by apoptosis and ne-
last dose of STZ, were significantly higher in crosis) (Finegood et al., 1995; Masiello,
males than females by about 75 % (356±18 2006). β-cell volume is 510 μm3 in rats
vs. 205±9 mg/dL) (Rossini et al., 1978); in ad- younger than 21 days, reaches 1020 μm3 at
dition, plasma glucose concentrations were about post-natal day 21, and remains constant
similar between castrated males and control after that, at least until 500 days (Finegood et
females and between testosterone-adminis- al., 1995). New pancreatic β-cells are formed
trated female and control males (Rossini et by neogenesis (differentiation from undiffer-
al., 1978). Castrated females had higher glu- entiated precursors such as embryonic duct
cose than control females, whereas castrated cells) mostly during gestation and also by rep-
males had lower plasma glucose than control lication (formation of new cells from preex-
males (Rossini et al., 1978). In another study, isting differentiated cells) mostly after birth
in C57BL/6J mice, following STZ (40 mg/kg, (Finegood et al., 1995). In rats older than 30-
IP) injection for 5 days, fasting blood glucose 40 days, the rate of β-cells duplication is
was about 50 % higher in males than females about 3 % per day and, along with hypertro-
(236±26 vs. 158±17 mg/dL) at 5 weeks after phy of β-cells (Finegood et al., 1995), plays a
STZ injection (Kim et al., 2020). Another significant role in the regulation of β-cell
study in C57BL/6 mice reported similar re- mass (Finegood et al., 1995; Butler et al.,
sults 8 weeks after STZ (55 mg/kg, IP, for 5 2003) with little contribution of neogenesis
consecutive days) injection, i.e., blood glu- (Finegood et al., 1995). β-cell replication in
cose was about 90 % higher in males than fe- rats is age-dependent (Finegood et al., 1995);
males (462±23 vs. 239±31 mg/dL). These it is highest at birth, reaches about 3 % by
data indicate that male rodents are more sen- post-natal days 30-40, and remains constant
sitive to STZ and tend to develop greater hy- after that (Finegood et al., 1995). β-cell repli-
perglycemia, as mentioned previously (Tesch cation in rats can be estimated by the equation
and Allen, 2007). The resistance of female provided by Finegood et al. (e=2.718)
mice to the diabetogenic effect of STZ can be (Finegood et al., 1995):
overcome by increasing the amount of in-
jected STZ; this issue has been reported in 𝛽 − 𝑐𝑒𝑙𝑙" 𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 " ("% " 𝛽" − 𝑐𝑒𝑙𝑙 𝑚𝑎𝑠𝑠/𝑑𝑎𝑦" )" =
C57BL/6J mice, where a higher dose of STZ 16.10 " "𝑒" ^(−0.065 × " 𝑝𝑜𝑠𝑡 − 𝑛𝑎𝑡𝑎𝑙 " 𝑎𝑔𝑒 ("𝑑𝑎𝑦𝑠" ) ) + 2.31
in females (75 mg/kg, IP for 5 consecutive
days) than males (55 mg/kg, IP for 5 consec- Unlike rats, replication and changes in β-
utive days) achieved same levels of hypergly- cell size have little importance in humans; in
cemia (Saadane et al., 2020). humans with type 2 diabetes, the neogenesis
rate is constant, and increased β-cell apoptosis
AGE-DEPENDENT SUSCEPTIBILITY is primarily involved in regulating β-cell mass
TO STZ (Butler et al., 2003).
Susceptibility to the diabetogenic effect of
The mass of β-cells in both humans STZ is inversely related to animal age; in
(Butler et al., 2003) and rodents (Finegood et male Wistar rats aged 25-50 days, higher
al., 1995) is dynamic, and the life span of rat doses of STZ are needed to induce diabetes
β-cells is 1-3 months (Finegood et al., 1995). successfully in younger rats (Masiello et al.,
Rat β-cell mass increases sharply after birth 1975, 1979). For example, the dose of STZ
(with a plateau in post-natal days of 5-20) un- needed to make diabetes in 50 g rats (about 25
til about post-natal day 100 and has a slower days of age) is twice higher than that required
growth after that (Finegood et al., 1995). for 150 g rats (about 50 days of age) (Masiello
285
et al., 1975). Age-dependent susceptibility to 2005). Wistar and Sprague-Dawley rats, the
STZ may be related to rats' decreased capacity most commonly-used rat strains for STZ-in-
for β-cell regeneration (Swenne, 1983). This duced diabetes, are sensitive to STZ (Samuel
notion is supported by findings that doses of et al., 2014).
STZ required for inducing diabetes in neona-
tal rats (80-100 mg/kg) are about 30-40 % APPROPRIATE ROUTE OF STZ
higher than doses in adult rats (60 mg/kg); in ADMINISTRATION
addition, neonatal STZ-induced diabetes in STZ is mostly injected through IV and IP
rats is characterized by rapid and spontaneous routes; however, intracardiac, subcutaneous,
recovery (Portha et al., 1974). In neonatal and intramuscular administration of STZ have
STZ rats, the β-cells number per pancreas is also been reported (Deeds et al., 2011;
about 50 % lower in n5-STZ compared to n0- Ghasemi et al., 2014). Intraperitoneal injec-
STZ rats, as measured 3 weeks later tion of STZ is easier, much more used, and
(0.44±0.04 × 106 vs. 0.84±0.07× 106) (Wang has a high reproducibility (Chaudhry et al.,
et al., 1996). Age-dependent reduction in in- 2013; Gvazava et al., 2020). However, it has
sulin secretion and elevation in blood glucose been found to be associated with risk of intes-
has also been reported in male Wistar rats; in tinal injury and mortality, and its penetration
the presence of glucose concentration of 5 into the subcutaneous tissue reduces its dia-
mM, the amount of insulin secreted from a betogenic effect (Deeds et al., 2011; Gvazava
single β-cell isolated from 24-months-old rats et al., 2020). Thus STZ dosage required to
was 34 % lower than 6-months-old rats achieve the same level of diabetes via the IP
(Perfetti et al., 1995). route is higher than the IV route (Tesch and
Allen, 2007). It has been reported that IV in-
STRAIN-DEPENDENT jection of STZ to mice produces a more repro-
SUSCEPTIBILITY TO STZ ducible and stable diabetic model (Tay et al.,
More than 1000 rat strains have been used 2005).
for research (Reed et al., 2011). Strain differ-
ence in the susceptibility to STZ has been re- RAT MORTALITY AFTER STZ
ported in mice (Kaku et al., 1989; Hayashi et INJECTION
al., 2006) and rats (Rodrigues et al., 1997). Following the injection of diabetogenic
Male Wistar-Kyoto rats are less sensitive to a doses (e.g., 65 mg/kg) of STZ, mortality is
moderate (55 mg/kg, IV) dose of STZ than due to severe hypoglycemia during the first
Wistar rats, as demonstrated with a lesser de- 24 h (Junod et al., 1967; Fischer and Rickert,
gree of non-fasted hyperglycemia (414±41 vs. 1975; Gajdosík et al., 1999) or severe hyper-
533±13 mg/dL) (Rodrigues et al., 1997). This glycemia that occurred after that (Junod et al.,
can be overcome by administrating a greater 1969). It has been reported that days 2 and 3
dose of STZ (75 mg/kg), which provided after STZ injection is the most critical period
comparable hyperglycemia between these
regarding the mortality rate (Gajdosík et al.,
two strains of rats (Rodrigues et al., 1997). In 1999). In a study in male Wistar rats, mortal-
addition, it has been shown that, unlike spon- ity rates were 1 out of 8, 2 out of 8, and 8 out
taneously hypertensive rats, male Wistar- of 8 during 2-3 days following 50, 60, and 70
Kyoto rats are resistant to the n2-STZ-in- mg/kg STZ injection (IV) to overnight-fasted
duced diabetic model (Iwase et al., 1987). animals (Gajdosík et al., 1999). Following
Dark Agouti (DA) and Albino Oxford (AO) STZ (65 mg/kg, IV) injection to fasted (24 h)
rats are susceptible to single high-dose male Sprague-Dawley rats, the six-week mor-
(SHD)-STZ-induced diabetes, but DA rats are tality rate was 12 % (3 out of 25) (Hoftiezer
highly vulnerable, and AO are resistant to and Carpenter, 1973).
multiple low-dose (MLD)-STZ-induced dia-
betes (Lukić et al., 1998; Howarth et al.,
286
Measures to prevent early hypoglycemia- Hyperglycemia-related mortality follow-

related mortality following STZ injection in ing injection of high doses of STZ can be
rats include providing access to food soon af- overcome with insulin administration (Junod
ter the injection (Junod et al., 1967, 1969), ad- et al., 1969). Rodent by non-fasting blood glu-
ministration of glucose (Fischer and Rickert, cose between 290-540 mg/dL can be main-
1975; Bar-On et al., 1976; Babu and tained without insulin injection, and those
Srinivasan, 1997; Palsamy and Subramanian, with non-fasting blood glucose higher than
2011) or sucrose (Tesch and Allen, 2007; 630 mg/dL needs insulin therapy (Tesch and
Ramzy et al., 2014) solutions in the first 24- Allen, 2007). The dose of insulin required
48 h after the injection, administration of the varies according to the severity of the disease,
drug to fed animals (Gajdosík et al., 1999), species, and strain and should be determined
and using the anomer-equilibrated solutions by the researcher (Tesch and Allen, 2007) but
of STZ (de la Garza-Rodea et al., 2010). is around 10-15 U/kg/day (Junod et al., 1969)
Early hypoglycemia-related mortality is or 2-4 U/rat/day (Tesch and Allen, 2007) of
more pronounced in fasted animals (Gajdosík subcutaneous injections of long-acting insu-
et al., 1999) and can be prevented by provid- lin.
ing rat access to food soon after injection
(Junod et al., 1967, 1969). Administration of CONCLUSION
glucose (10 % from 6-24 h after STZ injection Based on the presented discussion, a prac-
(Palsamy and Subramanian, 2011) and 5 % tical guide is provided in Figure 3 that can
during the first 24 h after STZ injection (Bar- help diabetes researchers to conduct better
On et al., 1976; Babu and Srinivasan, 1997)) studies. In addition, some points deserve fur-
and sucrose (10 % during 48 h after STZ in- ther attention and are briefly presented here.
jection (Ramzy et al., 2014) and 1.5 % during First, in addition to the intrinsic limitations of
48 h after STZ injection (Tesch and Allen, animal models, poor design and reporting of
2007)) solutions have been used to prevent animal studies are the main causes of poor
hypoglycemia-related early mortality in rats. concordance between preclinical and clinical
Administration of the STZ to the fed ani- outcomes (Perrin, 2014; Bahadoran et al.,
mals can also decrease hypoglycemia-related 2020). Further attention should be paid to re-
mortality (Gajdosík et al., 1999). Following porting the results of animal studies. Despite
the injection of high doses (100 mg/kg) of available guidelines on reporting results of
STZ to fasted rats, most rats died within 2-3 animal studies (Hooijmans et al., 2010;
days (Junod et al., 1969). Following STZ (50 Osborne et al., 2018; Percie du Sert et al.,
mg/kg, IP) injection to fasted (16 h) rats of 2020; Nagendrababu et al., 2021), a high
both sexes, 3 out of 6 rats died during 14 days number of papers fail appropriately report; for
(Mythili et al., 2004). On the other hand, after example, they do not provide animal age or
injection of STZ (100 mg/kg, IV) to non- sex (Kilkenny et al., 2009; Flórez-Vargas et
fasted rats, the mortality rate was 12.5 % after al., 2016), which can lead to a reproducibility
1 and 4 weeks and increased to 29 % after 16 crisis in biomedical research (Osborne et al.,
weeks (Tancrède et al., 1983). No mortality 2018). Thus, it is recommended to report de-
was reported when STZ was injected to non- tails in the method section, including animal
fasted male Wistar rats treated with doses ≤ age and sex, preparation of STZ, exact time of
65 mg/kg IV within 16 weeks (Tancrède et al., fasting before blood sampling, the success
1983) or ≤ 45 mg/kg IV to non-fasted male rate of inducing diabetes, and mortality rate
Sprague-Dawley rats within 12 days after in- (de la Garza-Rodea et al., 2010; Ghasemi et
jection (Bar-On et al., 1976). Only, one out of al., 2021). Second, considering the large body
six non-fasted male Sprague-Dawley rats died of evidence indicating sex differences in car-
following the IV injection of 55 mg/kg STZ bohydrate metabolism (Tarnopolsky and
within 12 days (Bar-On et al., 1976). Ruby, 2001; Basu et al., 2006; Wismann and
287
Willoughby, 2006; Franconi et al., 2008; results that have more chance to be translated
Macotela et al., 2009; Gustavsson et al., 2010, to humans. In addition, it helps to adhere to
2011; Marchese et al., 2015; Gannon et al., ethical issues in animal research, for example,
2018; Mauvais-Jarvis, 2018) and in STZ sen- by choosing the optimal dose of STZ that re-
sitivity in animals (Rossini et al., 1978; Kim duces the mortality rate and the number of an-
et al., 2020; Saadane et al., 2020), over-reli- imals used. Finally, differences between rats
ance on male-only animal models should be and humans should be considered in animal
avoided, and researchers should try to balance modeling, including differences in gene regu-
both sexes in the preclinical studies (Clayton lation, different life spans, and different met-
and Collins, 2014; McCullough et al., 2014; abolic rates (Wall and Shani, 2008). For
Ritz et al., 2014). Even most initial studies choosing an appropriate animal model for di-
that developed rat models of diabetes used abetes research, the purpose of the study, ani-
only male rats (see Table 1), a practice that mal sex, animal strain, and physiological rel-
needs revision. Third, diabetes researchers evance of the model used should be consid-
need a better understanding of animal models ered (King, 2012).
of diabetes —this issue helps to obtain robust
Figure 3: A practical guide for maintaining, preparing, and injecting streptozotocin (STZ) in STZ-based
rat models of diabetes. IV, intravenous; IP, intraperitoneal. Created with BioRender.com
288
Acknowledgments and funding information Bell RH Jr, Hye RJ. Animal models of diabetes melli-
This study was supported by a grant tus: physiology and pathology. J Surg Res. 1983;35:
433-60.
(Grant No. 43004018-7) from Shahid Be-
heshti University of Medical Sciences, Teh- Berger C, Zdzieblo D. Glucose transporters in pancre-
ran, Iran. atic islets. Pflugers Arch. 2020;472:1249-72.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza

Declaration of competing interest RA, Butler PC. Beta-cell deficit and increased beta-cell
The authors declare that they have no apoptosis in humans with type 2 diabetes. Diabetes.
competing interests. 2003;52:102-10.
Capdevila J, Ducreux M, García Carbonero R, Grande

Authorships E, Halfdanarson T, Pavel M, et al. Streptozotocin,
Asghar Ghasemi contributed to the litera- 1982-2022: Forty years from the FDA's approval to
ture review and wrote the article. Sajad Jeddi treat pancreatic neuroendocrine tumors. Neuroendocri-
and Asghar Ghasemi provided critical revi- nology. 2022;112:1155-67.
sion and final approval of the finalized manu- Carlson RV, Boyd KM, Webb DJ. The revision of the
script. All authors have read and approved the Declaration of Helsinki: past, present and future. Brit J
final manuscript. Clin Pharmacol. 2004;57:695-713.
Chaudhry ZZ, Morris DL, Moss DR, Sims EK, Chiong

Y, Kono T, et al. Streptozotocin is equally diabetogenic
REFERENCES whether administered to fed or fasted mice. Lab Anim.
Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi 2013;47:257-65.
S, Farhangi A, Verdi AA, et al. Induction of diabetes
by Streptozotocin in rats. Indian J 'Clin Biochem. Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng
2007;22(2):60-4. JT, et al. Phosphatidylinositol-3-kinase is involved in
the antihyperglycemic effect induced by resveratrol in
Anderson T, Schein PS, McMenamin MG, Cooney streptozotocin-induced diabetic rats. Life Sci. 2007;80:
DA. Streptozotocin diabetes. Correlation with extent of 1713-20.
depression of pancreatic islet nicotinamide adenine di-
nucleotide. J Clin Invest. 1974;54:672-7. Clayton JA, Collins FS. Policy: NIH to balance sex in
cell and animal studies. Nature. 2014;509:282-3.
Ar'Rajab A, Ahrén B. Long-term diabetogenic effect of
streptozotocin in rats. Pancreas. 1993;8:50-7. Cruz PL, Moraes-Silva IC, Ribeiro AA, Machi JF, de
Melo MDT, Dos Santos F, et al. Nicotinamide attenu-
Babu PS, Srinivasan K. Influence of dietary capsaicin ates streptozotocin-induced diabetes complications and
and onion on the metabolic abnormalities associated increases survival rate in rats: role of autonomic nerv-
with streptozotocin induced diabetes mellitus. Mol Cell ous system. BMC Endocr Disorders. 2021;21:133.
Biochem. 1997;175:49-57.
de la Garza-Rodea AS, Knaän-Shanzer S, den Hartigh
Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Im- JD, Verhaegen AP, van Bekkum DW. Anomer-equili-
portance of Systematic reviews and meta-analyses of brated streptozotocin solution for the induction of ex-
animal studies: challenges for animal-to-human trans- perimental diabetes in mice (Mus musculus). J Am As-
lation. J Am Assoc Lab Anim Sci. 2020;59:469-77. soc Lab Anim Sci. 2010;49:40-4.
Bar-On H, Roheim PS, Eder HA. Hyperlipopro- Deeds MC, Anderson JM, Armstrong AS, Gastineau
teinemia in streptozotocin-treated rats. Diabetes. DA, Hiddinga HJ, Jahangir A, et al. Single dose strep-
1976;25:509-15. tozotocin-induced diabetes: considerations for study
design in islet transplantation models. Lab Anim.
Basu R, Dalla Man C, Campioni M, Basu A, Klee G, 2011;45:131-40.
Toffolo G, et al. Effects of age and sex on postprandial
glucose metabolism: differences in glucose turnover, Defronzo RA. Banting Lecture. From the triumvirate
insulin secretion, insulin action, and hepatic insulin ex- to the ominous octet: a new paradigm for the treatment
traction. Diabetes. 2006;55:2001-14. of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.
Beery AK, Zucker I. Sex bias in neuroscience and bio-

medical research. Neurosci Biobehav Rev. 2011;35:
565-72.
289
El-Rashedy AHA-RH, Mostafa Wahdan MH, El-Sab- Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotina-
ban KA-FR, Khadrawy MA, Abu-Amara TM, Al- mide-induced rat model of type 2 diabetes (review).
Hamaky HA, et al. Role of fat feeding on the diabetic Acta Physiol Hung. 2014;101:408-20.
albino rats. J Cytol Histol. 2013;4(3):1000176.
Ghasemi A, Norouzirad R. Type 2 diabetes: An up-
Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen dated overview. Crit Rev Oncog. 2019;24:213-22.
S. Relative importance of transport and alkylation for
pancreatic beta-cell toxicity of streptozotocin. Diabeto- Ghasemi A, Jeddi S, Kashfi K. The laboratory rat: Age
logia. 2000;43:1528-33. and body weight matter. EXCLI J. 2021;20:1431-45.
Evan AP, Mong SA, Gattone VH, Connors BA, Ar- Gheibi S, Kashfi K, Ghasemi A. A practical guide for
onoff GR, Luft FC. The effect of streptozotocin and induction of type-2 diabetes in rat: Incorporating a
streptozotocin-induced diabetes on the kidney. Renal high-fat diet and streptozotocin. Biomed Pharma-
Physiol. 1984;7:78-89. cother. 2017;95:605-13.
Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of Gheibi S, Mahmoodzadeh A, Kashfi K, Jeddi S,

beta-cell mass in the growing rat pancreas. Estimation Ghasemi A. Data extraction from graphs using Adobe
with a simple mathematical model. Diabetes. 1995;44: Photoshop: applications for meta-analyses. Int J Endo-
249-56. crinol Metab. 2019;17(4):e95216.
Fischer LJ, Rickert DE. Pancreatic islet-cell toxicity. Goodman J, Chandna A, Roe K. Trends in animal use
CRC Crit Rev Toxicol. 1975;3:231-63. at US research facilities. J Med Ethics. 2015;41:567-9.
Flórez-Vargas O, Brass A, Karystianis G, Bramhall M, Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S,
Stevens R, Cruickshank S, et al. Bias in the reporting Patil CR, et al. Challenges and issues with streptozoto-
of sex and age in biomedical research on mouse mod- cin-induced diabetes - A clinically relevant animal
els. Elife. 2016;5:e13615. model to understand the diabetes pathogenesis and
evaluate therapeutics. Chem Biol Interact. 2016;244:
Franconi F, Seghieri G, Canu S, Straface E, Campesi I, 49-63.
Malorni W. Are the available experimental models of
type 2 diabetes appropriate for a gender perspective? Gustavsson C, Yassin K, Wahlström E, Cheung L,
Pharmacol Res. 2008;57:6-18. Lindberg J, Brismar K, et al. Sex-different hepaticgly-
cogen content and glucose output in rats. BMC Bio-
Frost PA, Chen S, Mezzles MJ, Voruganti VS, Nava- chem. 2010;11:38.
Gonzalez EJ, Arriaga-Cazares HE, et al. Successful
pharmaceutical-grade streptozotocin (STZ)-induced Gustavsson C, Soga T, Wahlström E, Vesterlund M,
hyperglycemia in a conscious tethered baboon (Papio Azimi A, Norstedt G, et al. Sex-dependent hepatic tran-
hamadryas) model. J Med Primatol. 2015;44:202-17. scripts and metabolites in the development of glucose
intolerance and insulin resistance in Zucker diabetic
Furman BL. Streptozotocin-Induced diabetic models in fatty rats. J Mol Endocrinol. 2011;47:129-43.
mice and rats. Curr Prot. 2021;1:e78.
Gvazava IG, Kosykh AV, Rogovaya OS, Popova OP,
Gajdosík A, Gajdosíková A, Stefek M, Navarová J, Sobyanin KA, Khrushchev AC, et al. A simplified
Hozová R. Streptozotocin-induced experimental dia- streptozotocin-induced diabetes model in nude mice.
betes in male Wistar rats. Gen Physiol Biophys. Acta Naturae. 2020;12:98-104.
1999;18(Spec No): 54-62.
Hayashi K, Kojima R, Ito M. Strain differences in the
Ganda OP, Rossini AA, Like AA. Studies on strepto- diabetogenic activity of streptozotocin in mice. Biol
zotocin diabetes. Diabetes. 1976;25:595-603. Pharm Bull. 2006;29:1110-9.
Gannon M, Kulkarni RN, Tse HM, Mauvais-Jarvis F. Hoftiezer V, Carpenter AM. Comparison of strepto-
Sex differences underlying pancreatic islet biology and zotocin and alloxan-induced diabetes in the rat, includ-
its dysfunction. Mol Metab. 2018;15:82-91. ing volumetric quantitation of the pancreatic islets. Di-
abetologia. 1973;9:178-84.
Gerich JE. Control of glycaemia. Bailliere's Clin Endo-
crinol Metab. 1993;7:551-86. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A
gold standard publication checklist to improve the
Gerich JE. Role of the kidney in normal glucose home- quality of animal studies, to fully integrate the Three
ostasis and in the hyperglycaemia of diabetes mellitus: Rs, and to make systematic reviews more feasible. Al-
therapeutic implications. Diabet Med. 2010;27:136-42. tern Lab Anim. 2010;38:167-82.
290
Howarth FC, Qureshi A, Shahin A, Lukic ML. Effects Kaku K, McGill J, Province M, Permutt MA. A single
of single high-dose and multiple low-dose streptozoto- major gene controls most of the difference in suscepti-
cin on contraction and intracellular Ca2+ in ventricular bility to streptozotocin-induced diabetes between
myocytes from diabetes resistant and susceptible rats. C57BL/6J and C3H/HeJ mice. Diabetologia. 1989;32:
Mol Cell Biochem. 2005;269:103-8. 716-23.
Hudson-Shore M. Statistics of scientific procedures on Kale VP, Joshi GS, Gohil PB, Jain MR. Effect of fast-
living animals Great Britain 2015 - highlighting an on- ing duration on clinical pathology results in Wistar rats.
going upward trend in animal use and missed opportu- Veter Clin Pathol. 2009;38:361-6.
nities. Altern Lab Anim. 2016;44:569-80.
Karunanayake EH, Hearse DJ, Mellows G. The synthe-
Iannaccone PM, Jacob HJ. Rats! Dis Model Mech. sis of [14C] streptozotocin and its distribution and ex-
2009;2(5-6):206-10. cretion in the rat. Biochem J. 1974;142:673-83.
IDF, International Diabetes Federation. IDF Diabetes Karunanayake EH, Hearse DJ, Mellows G. Strepto-
Atlas, 9th edn. Brussels, Belgium: IDF, 2019. Availa- zotocin: its excretion and metabolism in the rat. Dia-
ble at: https://www.diabetesatlas.org. betologia. 1976;12:483-8.
Islam MS, Choi H. Nongenetic model of type 2 diabe- Katada T, Ui M. Spontaneous recovery from strepto-
tes: a comparative study. Pharmacology. 2007;79:243- zotocin-induced diabetes in rats pretreated with pertus-
9. sis vaccine or hydrocortisone. Diabetologia. 1977;13:
521-5.
Islam MS, Loots du T. Experimental rodent models of
type 2 diabetes: a review. Methods Find Exp Clin Phar- Kilkenny C, Parsons N, Kadyszewski E, Festing MF,
macol. 2009;31:249-61. Cuthill IC, Fry D, et al. Survey of the quality of exper-
imental design, statistical analysis and reporting of re-
Islam MS, Wilson RD. Experimentally induced rodent search using animals. PloS One. 2009;4:e7824.
models of type 2 diabetes. In: Joost H-G, Al-Hasani H,
Schürmann A (eds) Animal models in diabetes re- Kim B, Kim YY, Nguyen PT-T, Nam H, Suh JG. Sex
search (pp 161-74). New York: Humana Press, 2012. differences in glucose metabolism of streptozotocin-in-
duced diabetes inbred mice (C57BL/6J). Appl Biol
Iwase M, Kikuchi M, Nunoi K, Wakisaka M, Maki Y, Chem. 2020;63:59.
Sadoshima S, et al. Diabetes induced by neonatal strep-
tozotocin treatment in spontaneously hypertensive and King AJ. The use of animal models in diabetes re-
normotensive rats. Metabolism. 1987;36:654-7. search. Brit J Pharmacol. 2012;166:877-94.
Jacob Filho W, Lima CC, Paunksnis MRR, Silva AA, Kleinert M, Clemmensen C, Hofmann SM, Moore MC,
Perilhão MS, Caldeira M, et al. Reference database of Renner S, Woods SC, et al. Animal models of obesity
hematological parameters for growing and aging rats. and diabetes mellitus. Nat Rev Endocrinol. 2018;14:
Aging Male. 2018;21:145-8. 140-62.
Johnson JH, Newgard CB, Milburn JL, Lodish HF, L'Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano
Thorens B. The high Km glucose transporter of islets V, Baldi S, et al. Beneficial effect of heme oxygenase-
of Langerhans is functionally similar to the low affinity 1 expression on myocardial ischemia-reperfusion in-
transporter of liver and has an identical primary se- volves an increase in adiponectin in mildly diabetic
quence. J Biol Chem. 1990;265:6548-51. rats. Am J Physiol Heart Circ Physiol. 2007;293:
H3532-41.
Junod A, Lambert AE, Orci L, Pictet R, Gonet AE,
Renold AE. Studies of the diabetogenic action of strep- Lebed YV, Orlovsky M, Lushnikova I, Skibo G. Neu-
tozotocin. Proc Soc Exp Biol Med. 1967;126:201-5. rodegenerative changes in the hippocampus within the
early period of experimental diabetes mellitus. Neuro-
Junod A, Lambert AE, Stauffacher W, Renold AE. Di- physiology. 2008;40:26-33.
abetogenic action of streptozotocin: relationship of
dose to metabolic response. J Clin Invest. 1969;48: Lee HB, Blaufox MD. Blood volume in the rat. J Nu-
2129. clear Med. 1985;26:72-6.
Kahn CR, Levy AG, Gardner JD, Miller JV, Gorden P, Lee JY, Kim MJ, Moon CK, Chung JH. Degradation
Schein PS. Pancreatic cholera: benefical effects of products of streptozotocin do not induce hyperglyce-
treatment with streptozotocin. N Engl J Med. 1975; mia in rats. Biochem Pharmacol. 1993;46:2111-3.
292:941-5.
291
Lenzen S. The mechanisms of alloxan- and strepto- McCullough LD, de Vries GJ, Miller VM, Becker JB,
zotocin-induced diabetes. Diabetologia. 2008;51:216- Sandberg K, McCarthy MM. NIH initiative to balance
26. sex of animals in preclinical studies: generative ques-
tions to guide policy, implementation, and metrics.
Levine BS, Henry MC, Port CD, Rosen E. Toxicologic Biol Sex Diff. 2014;5:15.
evaluation of streptozotocin (NSC 85998) in mice,
dogs and monkeys. Drug Chem Toxicol. 1980;3:201- Meier JJ. Beta cell mass in diabetes: a realistic thera-
12. peutic target? Diabetologia. 2008;51:703-13.
Lukić ML, Stosić-Grujicić S, Shahin A. Effector mech- Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC.
anisms in low-dose streptozotocin-induced diabetes. Sustained beta cell apoptosis in patients with long-
Dev Immunol. 1998;6:119-28. standing type 1 diabetes: indirect evidence for islet re-
generation? Diabetologia. 2005;48:2221-8.
MacLeod C, Rabin H, Ogilvie R, Ruedy J, Caron M,
Zarowny D, et al. Practical concepts of drug absorp- Mostafavinia A, Amini A, Ghorishi SK, Pouriran R,
tion, distribution and loss. Can Med Assoc J. 1974;111: Bayat M. The effects of dosage and the routes of ad-
341-6. ministrations of streptozotocin and alloxan on induc-
tion rate of type1 diabetes mellitus and mortality rate
Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and in rats. Lab Anim Res. 2016;32:160-5.
depot differences in adipocyte insulin sensitivity and
glucose metabolism. Diabetes. 2009;58:803-12. Mythili MD, Vyas R, Akila G, Gunasekaran S. Effect
of streptozotocin on the ultrastructure of rat pancreatic
Maejima K, Nagase S. Effect of starvation and refeed- islets. Microsc Res Techn. 2004;63:274-81.
ing on the circadian rhythms of hematological and
clinico-biochemical values, and water intake of rats. Nagendrababu V, Kishen A, Murray P, Nekoofar MH,
Jikken Dobutsu. 1991;40:389-93. de Figueiredo JAP, Priya E, et al. PRIASE 2021 guide-
lines for reporting animal studies in Endodontology:
Mak IW, Evaniew N, Ghert M. Lost in translation: an- explanation and elaboration. Int Endod J. 2021;54:
imal models and clinical trials in cancer treatment. Am 858-86.
J Transl Res. 2014;6:114-8.
Oles PJ. High-pressure liquid chromatographic separa-
Marchese E, Rodeghier C, Monson RS, McCracken B, tion and determination of anomeric forms of streptozo-
Shi T, Schrock W, et al. Enumerating β-cells in whole cin in a powder formulation. J Pharm Sci. 1978;67:
human islets: sex differences and associations with 1300-2.
clinical outcomes after islet transplantation. Diabetes
Care. 2015;38:e176-7. Olson H, Betton G, Robinson D, Thomas K, Monro A,
Kolaja G, et al. Concordance of the toxicity of pharma-
Masiello P. Animal models of type 2 diabetes with re- ceuticals in humans and in animals. Regul Toxicol
duced pancreatic beta-cell mass. Int J Biochem Cell Pharmacol. 2000;32:56-67.
Biol. 2006;38:873-93.
Osborne N, Avey MT, Anestidou L, Ritskes-Hoitinga
Masiello P, De Paoli A, Bergamini E. Age-dependent M. Improving animal research reporting standards:
changes in the sensitivity of the rat to a diabetogenic HARRP, the first step of a unified approach by ICLAS
agent (streptozotocin). Endocrinology. 1975;96:787-9. to improve animal research reporting standards world-
wide. EMBO Rep. 2018;19(5):e46069.
Masiello P, De Paoli AA, Bergamini E. Influence of
age on the sensitivity of the rat to streptozotocin. Hor- Palsamy P, Subramanian S. Resveratrol protects dia-
mone Res. 1979;11:262-74. betic kidney by attenuating hyperglycemia-mediated
oxidative stress and renal inflammatory cytokines via
Masiello P, Broca C, Gross R, Roye M, Manteghetti Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011;
M, Hillaire-Buys D, et al. Experimental NIDDM: de- 1812:719-31.
velopment of a new model in adult rats administered
streptozotocin and nicotinamide. Diabetes. 1998;47: Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey
224-9. MT, Baker M, et al. The ARRIVE guidelines 2.0: up-
dated guidelines for reporting animal research. J Phys-
Matsuzawa T, Sakazume M. Effects of fasting on hae- iol. 2020;598:3793-801.
matology and clinical chemistry values in the rat and
dog. Comp Haematol Int. 1994;4:152-6. Perfetti R, Rafizadeh CM, Liotta AS, Egan JM. Age-
dependent reduction in insulin secretion and insulin
Mauvais-Jarvis F. Gender differences in glucose home- mRNA in isolated islets from rats. Am J Physiol. 1995;
ostasis and diabetes. Physiol Behav. 2018;187:20-3. 269:E983-90.
292
Perrin S. Preclinical research: Make mouse studies Rossini AA, Williams RM, Appel MC, Like AA. Sex
work. Nature. 2014;507:423-5. differences in the multiple-dose streptozotocin model
of diabetes. Endocrinology. 1978;103:1518-20.
Portha B, Levacher C, Picon L, Rosselin G. Diabeto-
genic effect of streptozotocin in the rat during the per- Saadane A, Lessieur EM, Du Y, Liu H, Kern TS. Suc-
inatal period. Diabetes. 1974;23:889-95. cessful induction of diabetes in mice demonstrates no
gender difference in development of early diabetic ret-
Premilovac D, Gasperini RJ, Sawyer S, West A, Keske inopathy. PloS One. 2020;15:e0238727.
MA, Taylor BV, et al. A new method for targeted and
sustained induction of type 2 diabetes in rodents. Sci Samuel RO, Gomes-Filho JE, Dezan-Júnior E, Cintra
Rep. 2017;7(1):14158. LT. Streptozotocin-induced rodent models of diabetes:
Protocol comparisons. In: Elizabeth GL (ed) Strepto-
Ramzy MM, El-Sheikh AA, Kamel MY, Abdelwahab zotocin: Uses, mechanism of action and side effects (pp
SA, Morsy MA. Mechanism of testicular protection of 61-80). New York: Nova Science Publ., 2014.
carvedilol in streptozotocin-induced diabetic rats. In-
dian J Pharmacol. 2014;46:161-5. Santos EW, de Oliveira DC, Hastreiter A, da Silva GB,
de Oliveira Beltran JS, Tsujita M, et al. Hematological
Reed DR, Duke FF, Ellis HK, Rosazza MR, Lawler and biochemical reference values for C57BL/6, Swiss
MP, Alarcon LK, et al. Body fat distribution and organ Webster and BALB/c mice. Braz J Veter Res Anim
weights of 14 common strains and a 22-strain con- Sci. 2016;53:138-45.
somic panel of rats. Physiol Behav. 2011;103:523-9.
Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ
Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett transport and cytotoxicity. Specific enhancement in
JG, Gadbois TM, et al. A new rat model of type 2 dia- GLUT2-expressing cells. Diabetes. 1994;43:1326-33.
betes: the fat-fed, streptozotocin-treated rat. Metabo-
lism. 2000;49:1390-4. Shanks N, Greek R, Greek J. Are animal models pre-
dictive for humans? Philos Ethics Humanit Med. 2009;
Rees DA, Alcolado JC. Animal models of diabetes 4:2.
mellitus. Diabet Med. 2005;22:359-70.
Shuster E. Fifty years later: the significance of the Nu-
Ritz SA, Antle DM, Côté J, Deroy K, Fraleigh N, remberg Code. N Engl J Med. 1997;337:1436-40.
Messing K, et al. First steps for integrating sex and gen-
der considerations into basic experimental biomedical Singh VK, Seed TM. How necessary are animal mod-
research. FASEB J. 2014;28:4-13. els for modern drug discovery? Expert Opin Drug Dis-
cov. 2021;16:1391-7.
Rizza RA, Gerich JE, Haymond MW, Westland RE,
Hall LD, Clemens AH, et al. Control of blood sugar in Sluiter W, Oomens LW, Brand A, Van Furth R. Deter-
insulin-dependent diabetes: comparison of an artificial mination of blood volume in the mouse with 51chro-
endocrine pancreas, continuous subcutaneous insulin mium-labelled erythrocytes. J Immunol Meth. 1984;
infusion, and intensified conventional insulin therapy. 73:221-5.
N Engl J Med. 1980;303:1313-8.
Snyder W, Cook M, Nasset E, Karhausen L, Tipton I.
Robbins MJ, Sharp RA, Slonim AE, Burr IM. Protec- Report of the task group on reference man. Report Pre-
tion against streptozotocin-induced diabetes by super- pared for International Commission on Radiological
oxide dismutase. Diabetologia. 1980;18:55-8. Protection. Oxford: Pergamon Press, 1975; repr. 1992.
(International Commission on Radiological Protection,
Rodrigues B, Cam MC, Kong J, Goyal RK, McNeill No. 23).
JH. Strain differences in susceptibility to streptozoto-
cin-induced diabetes: effects on hypertriglyceridemia Spanheimer RG. Collagen production in bone and car-
and cardiomyopathy. Cardiovasc Res. 1997;34:199- tilage after short-term exposure to streptozotocin. Ma-
205. trix. 1989;9(2):172-4.
Rossini AA, Like AA, Chick WL, Appel MC, Cahill Srinivasan K, Ramarao P. Animal models in type 2 di-
GF Jr. Studies of streptozotocin-induced insulitis and abetes research: an overview. Indian J Med Res. 2007;
diabetes. Proc Natl Acad Sci U S A. 1977a;74:2485-9. 125:451-72.
Rossini AA, Like AA, Dulin WE, Cahill GF Jr. Pan- Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao
creatic beta cell toxicity by streptozotocin anomers. Di- P. Combination of high-fat diet-fed and low-dose
abetes. 1977b;26:1120-4. streptozotocin-treated rat: a model for type 2 diabetes
and pharmacological screening. Pharmacol Res. 2005;
52:313-20.
293
Stauffacher W, Burr I, Gutzeit A, Beaven D, Velemin- Tripathi V, Verma J. Different models used to induce
sky J, Renold AE. Streptozotocin diabetes: time course diabetes: a comprehensive review. Int J Pharm Pharm
of irreversible B-cell damage; further observations on Sci. 2014;6:29-32.
prevention by nicotinamide. Proc Soc Exp Biol Med.
1970;133:194-200. Wall RJ, Shani M. Are animal models as good as we
think? Theriogenology. 2008;69:2-9.
Su HC, Hung LM, Chen JK. Resveratrol, a red wine
antioxidant, possesses an insulin-like effect in strepto- Wang RN, Bouwens L, Klöppel G. Beta-cell growth in
zotocin-induced diabetic rats. Am J Physiol Endocrinol adolescent and adult rats treated with streptozotocin
Metab. 2006;290:E1339-46. during the neonatal period. Diabetologia. 1996;39:
548-57.
Swenne I. Effects of aging on the regenerative capacity
of the pancreatic B-cell of the rat. Diabetes. 1983;32: Weingand K, Brown G, Hall R, Davies D, Gossett K,
14-9. Neptun D, et al. Harmonization of animal clinical pa-
thology testing in toxicity and safety studies. The Joint
Tancrède G, Rousseau-Migneron S, Nadeau A. Long- Scientific Committee for International Harmonization
term changes in the diabetic state induced by different of Clinical Pathology Testing. Fund Appl Toxicol.
doses of streptozotocin in rats. Brit J Exp Pathol. 1983; 1996;29:198-201.
64:117-23.
Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S.
Tarnopolsky MA, Ruby BC. Sex differences in carbo- Islet secretion in a new experimental model for non-
hydrate metabolism. Curr Opin Clin Nutr Metab Care. insulin-dependent diabetes. Diabetes. 1981;30:590-5.
2001;4:521-6.
Wismann J, Willoughby D. Gender differences in car-
Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, bohydrate metabolism and carbohydrate loading. J Int
Harris DC. Can murine diabetic nephropathy be sepa- Soc Sports Nutr. 2006;3:28-34.
rated from superimposed acute renal failure? Kidney
Int. 2005;68:391-8. Xu J, Zhang L, Chou A, Allaby T, Bélanger G, Radziuk
J, et al. KATP channel-deficient pancreatic beta-cells
Taylor K, Gordon N, Langley G, Higgins W. Estimates are streptozotocin resistant because of lower GLUT2
for worldwide laboratory animal use in 2005. Altern activity. Am J Physiol Endocrinol Metab. 2008;294:
Lab Anim. 2008;36:327-42. E326-35.
Tesch GH, Allen TJ. Rodent models of streptozotocin- Zheng Y, Ley SH, Hu FB. Global aetiology and epide-
induced diabetic nephropathy. Nephrology. 2007;12: miology of type 2 diabetes mellitus and its complica-
261-6. tions. Nat Rev Endocrinol. 2018;14:88-98.
Thurston DE, Pysz I. Chemistry and pharmacology of Zimmet PZ. Diabetes and its drivers: the largest epi-
anticancer drugs. 2nd ed. Boca Raton, FL: CRC Press, demic in human history? Clin Diabetes Endocrinol.
2021. 2017;3:1.
294

STZ Induced Diabetes

Uploaded by

Copyright:

Available Formats

STZ Induced Diabetes

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

STZ Induced Diabetes

Uploaded by

Copyright:

Available Formats

EXCLI Journal 2023;22:274-294 – ISSN 1611-2156

Asghar Ghasemi , Sajad Jeddi*

Endocrine Physiology Research Center, Research Institute for Endocrine Sciences,

* Corresponding author: Sajad Jeddi, Ph.D., Endocrine Physiology Research Center,

Keywords: Animal model, rat, streptozotocin, diabetes

INTRODUCTION pathophysiology of diabetes to improve dia-

Table 1: Rat models of streptozotocin (STZ) diabetes

STREPTOZOTOCIN STZ metabolism in rats

Dose-dependent effects of STZ on

rapid equilibrium between extracellular and

Different sensitivity to STZ-induced dia- Mass of β-cells is regulated by the balance in

Measures to prevent early hypoglycemia- Hyperglycemia-related mortality follow-

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza

Capdevila J, Ducreux M, García Carbonero R, Grande

Chaudhry ZZ, Morris DL, Moss DR, Sims EK, Chiong

Beery AK, Zucker I. Sex bias in neuroscience and bio-

Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of Gheibi S, Mahmoodzadeh A, Kashfi K, Jeddi S,

You might also like